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I CHAPTER 185 
Intestinal and Multiple Organ 
Transplantation 
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The concept and practice of intestinal transplantation were 
born together with those for kidney and liver transplanta-
tion. After the introduction of cyclosporin A, transplantation 
of these other organs enjoyed rapid clinical applicability. 
Success with intestinal transplantation, however, remained 
blurred because of a high incidence of graft loss due to 
rejection. infection, and technical complications.! 
The first experimental attempts at intestinal transplanta-
tion were reported by Lillehei and coworkers in 1959 as an 
isolated organ graft in dogs.2 One year later, Starzl and 
Kaupp included the small bowel as part of a multi visceral 
graft in dogs (liver, stomach, pancreaticoduodenal complex, 
small and large intestine).3 The first human application of a 
modified form of this operation was the transplantation of 
a "cluster" of organs in 1989.4 This allograft consisted of 
liver and pancreaticoduodenal complex after upper abdom-
inal exenteration for malignancy (Fig. 185-1). Viability of 
varying lengths of intestine with these clusters was proven, 
as was evidence of regeneration after severe rejection-in-
duced injury. The inclusion of the liver in this type of graft 
was believed to protect the other organs transplanted from 
the same donor against rejection.J · S.' 
In 1987, a 3-year-old girl received a multivisceral abdom-
inal graft that contained the stomach. duodenum, pancreas, 
small bowel. colon. and liver. She had an extended survival 
of 6 months with intestinal graft function.' An even longer 
survival of 1 year was obtained in a recipient of a liver and 
small bowel graft treated by Grant and associates· Until 
Figure 185-1. Cluster allograft (shaded portion), including the liver, 
pancreas, and duodenal segment of small intestine. (From Starzl 
TE, Todo S. Tzakis A. et al: Abdominal organ cluster transplanta-
tion for the treatment of I,lpper abdominal malignancies. Ann 5urg 
1989; 210:374-386.) 
1990, there had been only two survivors of isolated cadav-
eric intestinal grafting.'· !O 
INDICATIONS 
Loss of intestinal function may be acute (e.g., necrotizing 
enterocolitis, volvulus. mesenteric thrombosis) or chronic 
(e.g., Crohn's disease, radiation enteritis). Candidate classi-
fication can be approached with an arbitrary division of 
surgical and nonsurgical cause. Patients with surgical 
causes generally suffer from loss of bowel length after resec-
tions for atresias, infarctions (e.g., volvulus, vascular catas-
trophes, necrotizing enterocolitis), or strictures and fistulas 
as with Crohn's disease. With nonsurgical causes of intes-
tinal failure, the anatomic length and gross morphology 
may be normal. These causes include motility disorders 
(e.g., intestinal pseudo-obstruction, Hirschsprung's disease). 
absorptive insufficiencies (e.g., microvillus inclusion dis-
ease), polyposis syndromes, and incarcerating desmoid tu-
mors. 
Total parenteral nutrition has become the standard of care 
for patients who are unable to maintain a normal nutritional 
state by use of the gastrointestinal tract alone (intestinal 
failure).'! Transplantation of the intestine either alone or 
accompanied by other intra-abdominal organs (liver, stom-
ach, pancreas) may be beneficial in these patients. since the 
stability and duration of total parenteral nutrition therapy 
varies, depending on complicating factors such as infection, 
metabolic disorders. difficulty with vascular access, and 
liver dysfunction. I1 
The decision regarding allograft composition focuses on 
the integrity of the remaining gut and other abdominal or-
gans. both functionally ,md anatomically. Guidelines used 
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TABLE 185-1. Partial and Complete Intestinal Allografts 
Organ Transplanted 
Multivisceral (stomach, 
duodenum, pancreas, liver, 
small bowel, colon) 
Liver and small intestine 
Liver, duodenum, and pancreas 
(organ cluster 
transplantation) 
Small intestine 
Indication 
Pseudo-obstruction/' 
aganglionosis syndrome with 
hepatic failure; diffuse 
splanchnic venous 
thrombosis and hepatic 
failure 
Hepatic failure after prolonged 
hyperalimentation for short 
gut syndrome 
After upper abdominal 
exenteration for malignancy 
Congenital or acquired absence 
or dysfunction 
in substantiating the need for concomitant liver replacement 
in these intestinal transplantation candidates are biochemi-
cal dysfunction (hyperbilirubinemia, transaminase abnor-
malities, hypoalbuminemia, and coagulopathy), pathologic 
processes (fibrosis or cirrhosis on liver biopsy), and the clin-
ical presence of portal hypertension as manifested by hepa-
tosplenomegaly, ascites, or esophageal varices. Patients de-
ficient in protein 5, protein C, and antithrombin III (liver-
derived) should receive a combined liver-small intestine 
allograft. Recipients lacking these substances develop dif-
fuse thromboses within the splanchnic system and undergo 
transplantation for mesenteric venous hypertension rather 
than for intestinaJ insufficiency.12 Patients with motility dis-
orders that involve the entire gastrointestinal tract are can-
didates for replacement of this entire system (Table 185-1). 
Table 185-2 lists the causes for intestinal failure in pa-
tients who underwent transplantation at the University of 
Pittsburgh. Inability to continue total parenteral nutrition 
because of the development of hepatic cirrhosis and venous 
access limitations were the most frequent indications for 
transplantation. 
ABDOMINAL VISCERAL PROCUREMENT 
The safe procurement of multiple visceral organs, either en 
bloc or as separate components, hinges on a few fundamen-
tal precepts. Conceptually, the focus is to isolate and cool 
the organs, thus preserving their vascular and parenchymal 
anatomy. Multivisceral en bloc retrieval including the stom-
ach, duodenum, pancreas, liver, and small intestine is the 
parent operation, and the assembled components have been 
likened by Starzl and colleagues to a large clump of individ-
ual grapes from the whole.13 An appreciation of the funda-
TABLE 185-2. Indications for Composite and Isolated Intestinal 
Transplantation in 33 Patients at the University of Pittsburgh 
from May 1990 to January 1993 
Pediatric Patients (48%) Adult Patients (52%) 
Necrotizing enterocolitis 29% Crohn's disease 31% 
Gastroschisis 21% Thrombolytic disorder 25% 
Volvulus 17% Trauma 16% 
Pseudo-obstruction 13% Pseudo-obstruction 9% 
Hirschsprung's disease 7% Radiation enteritis 6% 
Intestinal atresia 7% Desmoid tumor 5% 
Microvillus inclusion 3% Familial polyposis 4% 
disease 
Malrotation 3% Volvulus 4% 
mental strategy of multivisceral organ retrieval leads to an 
understanding of the lesser variant operations-that is, 
liver, small intestine, combined liver-small intestine, and 
organ cluster (liver, duodenum, and pancreas) transplanta-
tion. A more complete discussion of the specifics of organ 
procurement is presented in Chapter 178. 
RECIPIENT OPERA nONS 
Most patients who need intestinal or multiorgan replace-
ments have had multiple forays into the abdominal cavity 
for intestinal resections, lengthening procedures, and treat-
ment of complications. This results in volume contraction of 
the abdominal cavity and severe adhesions. For this reason, 
the organs of the donor need to be smaller than those of the 
recipient to allow proper abdominal closure. 
Previous operations may complicate the removal of the 
recipient's organs, especially if cirrhosis, portal hyperten-
sion, or inferior vena caval thromboses are present, all of 
which may be sequelae of the original disease or of prior 
operations. The recipient's operation consists of removal of 
the failed organs with exposure of the vascular anatomy 
and, finally, allograft implantation. Following is a brief de-
scription of the salient features of the recipient operations. 
Multivisceral Transplantation 
After essentially abdominal exenteration and exposure of 
the retroperitoneal aorta and inferior vena cava have been 
performed, the multivisceral graft (Fig. 185-2) is connected 
by its vascular attachments: first the suprahepatiC attach-
ment, then infrahepatic vena caval connections, and finally 
the arterioaortic anastomosis. The recipient's portal vein 
and its outflow and inflow organs (gastrointestinal tract, 
pancreas, and liver) are removed with the enterectomy. The 
donor portal vein retains its continuity via the liver in the 
procurement of the allograft; thus, no portal vein anasto-
mosis is required in this procedure. 
Restoration of intestinal continuity requires an esophago-
gastric anastomosis and a coloenteric anastomosis with the 
distal ileum allograft. Initially, the patient also receives an 
ileostomy (see Fig. 185-2). Takedown of the ileostomy can 
be performed after several months, when oral nutrition is 
consistently adequate, a stable immunosuppressant regimen 
has been achieved, and the need for frequent endoscopic 
surveillance has lessened. 
Liver-Small Bowel 
Liver and small intestine are removed in these patients, but 
the remainder of the foregut (stomach, duodenum, pan-
creas) is retained. When possible, the liver is removed with 
the retrohepatic vena cava preserved in situ.14 After the 
enterectomy, the composite allograft is implanted by anas-
tomosing the suprahepatic vena cava of the donor (includ-
ing the hepatic veins) end-ta-side to the recipient's vena 
cava. The donor infrahepatic vena cava can then be ligated. 
The double arterial stem of the celiac and superior mesen-
teric arteries (using the Carrel button technique) are con-
nected to the infra renal aorta with subsequent graft reper-
fusion. Since the axial stem of the portal vein between the 
donor organs has remained intact, all that is required for 
the completion of portal flow is attachment of the portal 
vein of the remnant foregut in the recipient to the intact 
portal stem of the donor (Fig. 185-3). This may not be pos-
sible, however, beca'use of size discrepancy or difficult ana-
tomic relationships between donor and recipient portal 
veins. In this case, a permanent portocaval shunt is per-
-
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Figure 185-2. Diagrams of muitivisceral donor organs before (Al and after (8) implantation show the suprahepatic and infrahepatic vena 
caval and arterioaortic anastomoses. Abbreviations: Ive = inferior vena cava; PV = portal vein. (From Starzl TE, Todo S, Tzakis A, el al: 
The many faces of multivisceral transplantation. Surg Gynecol Obstet 1991; 172:335-344. By permission of Surgery, Gynecology & 
Obstetrics. ) 
formed. The intestinal anastomoses are then completed with 
a proximal jejunojejunostomy, ileocolostomy, and Roux-en-
Y biliary anastomoses (see Fig. 185-3). A temporary distal 
ileostomy is also provided. 
Isolated Small Bowel 
After wide exposure, the recipient's small intestine is re-
moved from the ligament of Treitz to the colon. The supe-
rior mesenteric artery of the donor bowel is sewn to the 
infra rena I aorta, and the donor superior mesenteric vein to 
the recipient portal vein or, alternatively, the donor superior 
mesenteric vein is anastomosed to the recipient's inferior 
vena cava (Fig. 185-4). Reperfusion of the graft is effected 
after the vascular anastomoses. Intestinal continuity is com-
pleted with proximal and distal anastomoses, and access to 
the ileum for endoscopic examination is provided by a tem-
porary chimney ileostomy.'5 ' 
Cold ischemia refers to the time between procurement 
and implantation of the allograft; for best results, whenever 
a segment of the intestine is included, this period should be 
less than 10 hours to avoid preservation injury. Warm ische-
mic time for the allograft (sewing-in time) is about 30 min-
utes and is also a determinant of preservation injury to the 
intestine. 
IMMUNOSUPPRESSION 
Immunosuppression is similar in recipients of small bowel, 
liver-small bowel, cluster, and multivisceral transpl;mts. 
One gram of intravenous hydrocortisone (for children) or 
methylprednisolone (for adults) is given immediately J Itn 
graft reperfusion. Administration of FK-506 (0.15-0.2 Ill)j . 
kg- J • d- I ) is then begun by continuous intravenous infu-
sion, with steady-state plasma levels between 2 and 3 ng/ 
mL as targets. A steroid taper of methylprednisolone is 
started at a dose of 100 mg (for children) or 200 mg (for 
adults) and reduced over a period of 5 days to 10 mg (for 
children) or 20 mg (for adults) per day. In some cases, aza-
thioprine may be added to mitigate the nephrotoxicity <lnd 
neurotoxicity of the FK-506. As gastrointestinal motilitv re-
sumes, oral FK-S06 given twice daily may be used to sup-
plement the intravenous regimen, which is gradually tJ-
pered. 
Induction therapy as well as chronic maintenance therapy 
involves the use of two and often three drugs. However, If 
organ tolerance with minimal rejection episodes is demon-
strated, gradual reduction ilnd even cessation of sterOid 
therapy may be possible. 
Prostaglandin EI (Prostin) is administered, 0.003 to 0.009 
mg . kg - I . min - I, for the first 5 postoperative days. This IS 
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Figure 185-3. Combined liver-small intestinal allograft. A, After removal from donor; note the intact portal venous axial stem and the 
common origin from the aortic patch of the celiac and superior mesenteric arteries (CA and SMA, respectively). B, After transplantation, a 
single upper caval and arterioaortic anastomosis is done before reperfusion. Recipient PV to donor PY shunt allows venous outflow of 
retained pancreas and stomach from recipient. (From Starzl TE, Todo S, Tzakis A, et a1: The many faces of multivisceral transplantation. 
Surg Gynecol Obstet 1991; 172:335-344. By permission of Surgery, Gynecology & Obstetrics.) 
given both for its beneficial effects on renal perfuSion as 
well as for its prevention of microvascular thromboses, the 
damage-mediating event in acute cellular rejection and pro-
curement injury.'· 
POSTOPERATIVE CARE 
Recipients of multivisceral, liver-small bowel, or cluster 
grafts commonly suffer from severe liver failure. Therefore, 
the care with respect to lungs, infection surveillance, and 
liver graft function is similar to that for routine liver trans-
plant recipients. Recipients of isolated small bowel trans-
plants who have stable liver function have a lesser preoper-
ative medical acuity. 
Ventilatory Management 
Extubation can often be accomplished within 48 hours of 
transplantation. Unusual circumstances such as graft mal-
function, sepsis, inability to close the abdominal wall, or 
severe preoperative hepatic failure may prevent early extu-
bation. Since the operation is quite long (8-18 hours) and 
the patients are often in <I weakened nutritional state pre-
operatively, a c<lreful assessment of weaning parameters is 
required. The negative inspiratory force, forced vital capac-
ity, and spontaneous minute ventilation are most important. 
It is wise to observe the patients for several hours while 
they remain intubated on continuous positive airway pres-
sure to make certain that they can tolerate the withdrawal 
of mechanical support and extubation. Incisional pain, as-
cites, and pleural effusions may compromise ventilation and 
the ability to cough. Muscle wasting and malnutrition, par-
tial or complete paralysis of the right hemidiaphragm,17 and 
occasional discrepancies in donor/recipient size that pro-
duce an increased intra-abdominal volume with compres-
sion of the thoracic cavity may be factors responsible for 
respiratory impairment. These patients often require low 
doses of intravenous narcotics, repeated thoracentesis and 
paracentesis, and supplemental extensive respiratory ther-
apy if they are to avoid the need for reintubation. Many 
patients have required tracheostomies because of the need 
for prolonged ventilatory support. 
Renal Function 
Early follOWing transplantation, there is significant intersti-
tial accumulation of fluid into the graft, lung, and peripheral 
tissues; this accumulation peaks at 48 to 72 hours. Extensive 
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volume shifts into the transplanted bowel Ere~4ted to pres-
ervation injury) and heavy ascites production. (related to 
mesenteric lymphatic leakage) lead to intravascular volume 
depletion, which can exacerbate the nephrotoxicity of FK-
506 and certain antibiotics. Continuous central venous pres-
sure measurement, often for weeks following transplanta-
tion, provides important information for maximizing graft 
perfusion and preserving the integrity of the kidneys. 
Infection Control 
Recipients of isolated or composite small bowel grafts re-
ceive prophylactic, broad-spectrum intravenous antibiotics. 
Any history of recent nosocomial infections before trans-
plantation should be addressed with the administration of 
appropriate specific antibiotics. Colonizing organisms grow-
ing from enterocutaneous fistulous tracts should be treated 
perioperatively. 
All recipients are given a "cocktail" of oral nonabsorbable 
antibiotics every 6 hours for 1 month; the mix includes 
amphotericin B, gentamicin, and polymixin E and is in-
tended to achieve selective bowel decontamination.'" Sur-
veillance stool cultures are performed every 3 days. If any 
organisms grow in quantitative cultures to colonies of 
greater than 10" organisms and if the patient demonstrates 
signs of systemic sepsis, or if there is ongoing acute cellular 
rejection of the allograft, then specifically directed intrave-
nous antibiotics are added to the regimen to treat the pre-
sumed translocating organisms. This most commonly occurs 
during episodes of acute rejection, when the mucosal barrier 
of the allograft has been immunologically damaged. 
Routine prophylaxis to prevent cytomegalovirus infection 
includes a 2-week course of intravenous ganciclovir while 
Figure 185-4. lllustr<1tion of an isolated 
small bowel graft shOWing mesenteric 
venous and arterial connections. The distal 
ileal chimney allows easy access to bowel 
mucosa. (From Todo S, Tzakis A, Abu-
Elmagd K, et al: Intestinal transplantation 
in composite visceral grafts or alone. Ann 
Surg 1992; 216:223-234.) 
lifetime oral trimethoprim-sulfamethoxazole is used as pro-
phylaxis for pneumocystis pneumonia. 
Nutritional Support 
Standard total parental nutrition formulas are tapered grad-
ually as oral or enteral feedings (via gastric or jejunal tube) 
are advanced. Tube feedings are initiated with an isotonic 
dipeptide formula containing medium-chain triglycerides 
and glutamine. This is later converted to a lactose- and 
gluten-free diet that contains dietary fibers to promote nor-
malization of intestinal motility and function. Most patients 
do not voluntarily eat adequate amounts early after the 
operation; therefore, enteral supplementation is required 
when the intestinal tract becomes functional. This resistance 
to resumption of oral feedings has been particularly impres-
sive in pediatric recipients." 
Assessment of Graft Status 
A judgment of the anatomic and functional integrity of the 
graft begins in the operating room. The normal <lppe<lrancl' 
of the mesentery and intestine is pink and nonedematous 
with the intestine occasionally demonstrating contractions. 
Alterations from this appearance can be observed in the 
operating room and in the ileal stoma postoperatively. 
Surveillance for intestinal graft rejection focuses on clini-
cal evaluation and gross morphologic examination of the 
stoma and the distal ileum with enteroscopy. EndoscopIC 
evaluations are performed routinely twice a week through 
the allograft ileostomy, whereas upper endoscopy is per-
formed as indicated. Grossly, the bowel reacts to insult .IIl 
nonspeCific ways with edema, cyanosis, congestion, and Ill' 
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creased stomal output; these alterations should signal a 
broad differential to include preservation injury, systemic 
sepsis, rejection, and enteritis. 
The stomal output is assessed for \'olume, consistency, 
and the presence of reducing substances, which can be seen 
in the event of rejection, bacterial overgrowth, or malab-
sorption. Typical stomal output of a clear, watery effluent 
within the first week of implantation is 1 to 2 Lid for adults 
and 40 to 60 mLlkg per day for children. If these volumes 
are exceeded and no significant pathology is present, pare-
goric, loperamide, pectin, somatostatin, or oral antibiotics 
may be utilized singly or in combination to control the diar-
rhea. The presence of blood in the stool is always an omi-
nous sign and must be assumed to indicate rejection until it 
is proved otherwise. 
Serum tests are important to give indications of possible 
anatomic injury to the liver (bilirubin, aspartate aminotrans-
ferase, and alanine aminotransferase), but no such tests exist 
for the intestinal grafts. Serum markers for nutritional ade-
quacy and anabolic status (transferrin, albumin, retinoic 
acid) are of limited value, whereas specific tests of the ab-
sorptive ability of the graft are good measures of overall 
function. Assessment of small bowel function relies on ab-
sorption studies of D-xylose and FK-506 and on th~ quanti-
tation of fat in the stool. Most patients develop satisfactory 
absorption curves for D-xylose within the first postoperative 
month, with absorption improving over time. Abnormal re-
sults obtained after 1 month should always prompt an ag-
gressive search for underlying pathology, especially rejec-
tion. The maintenance of satisfactory FK-506 plasma trough 
levels of 2 to 3 nglmL on oral therapy alone is a good 
indicator of adequate absorption. In our patients, this has 
occurred at a mean of 28 days after transplantation and 
tends to be delayed longer in recipients of multivisceral 
grafts.'· The excretion of fat in the stool has been abnormal 
in almost all patients. However, clinical steatorrhea has not 
been a problem. 
Figure 185-5. Severely damaged allograft intestine in J recipient of 
a liver-small bowel after multiple episodes of rejection. Diffuse 
tubulized gut, strictures, and significant distention of the native 
duodenum are seen. 
Radiologic evaluations by standard barium gastrointes-
tinal examination are valuable in assessing mucosal pattern 
and motility and are performed routinely ilfter the first post-
operative week. A normill mucosal p,lItern is expected. In-
testinal transit time is around 2 hours. Intestinal gr,lft rejec-
tion, when mild, can be suspected whell evidence of 
mucosal edema exists. Severe rejection, with exfoliiltion of 
the mucosa, ablates the normal mucosal pattern ,lOd can be 
seen as segments of "tubulized" intestine and strictures 
(Fig. 185-5). 
COMPLICA nONS 
Before a description of the variety of potential complica-
tions, it is important to have a general perspective on the 
care of these patients. Comprehensive management of intes-
tinal recipients requires a multidisciplinary approach by 
surgeons, anestheSiologists, nurses, critical care physicians, 
pathologists, and a host of internal medicine subspecialists. 
Easy access to diagnostic and therapeutic modalities, includ-
ing mechanical ventilation, hemodialysis, bronchoscopy, 
gastrointestinal endoscopy, thromboelastography, percuta-
neous cholangiography, ultrasonography, invasive and non-
invasive contrast radiography, and sophisticated hemody-
namic monitoring systems, is paramount. 
More important than the above, however, is a vigilance 
about patient care and attention to detail, on the part of 
both physicians and nurses. Problems in these patients can 
originate from a multiplicity of sources. Several assump-
tions can be made in these patients based on our experience: 
1. Preoperative deterioration of physical performance sta-
tus predisposes to various organ system failure that persists 
in the postoperative period even though allograft function 
may be acceptable. 
2. Transplant patients are labor intensive and require ag-
gressive respiratory therapy, nutritional and antibiotic sup-
II ,
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port. Iluid management, and nursing care, often for pro-
longed periods in the intensive care unit. 
1. lInmunother,lpv dose's in patients with Illultivisceral 
transpl,l11ts tend to be hIgher than in patients with smgll' 
orgilll trilllsplilnts. . . . 
-I. The majority oi patIents develop episodes 01 intectlOn 
ilnd rejection after transplantation, often concOimtantly. Any 
subjective complaints or objective ilbnormalities should be 
vigorously pursued until a Ciluse is found or until they 
resolve. 
Graft Rejection 
Intestinal allograft rejection can present ilS an array of symp-
toms that include iever, "l,dominal pain, distention, nausea, 
vomiting, and a sudden increase in stomal output. The 
stoma may become edematous, erythematous, and friable. 
Gastrointestinal bleeding can occur in cases of severe uncon-
trollable rejection in which ulcerations and sloughing of the 
intestinal mucosa occur. Septic shock or acute respiratory 
distress syndrome'may develop. Bacterial or fungal translo-
cation can occur during intestinal allograft rejection due to 
disruption of the intestinal mucosal barrier. Gut decontami-
nation must be in,stituted during these episodes.20 
Endoscopically, the transplanted intestinal mucosa loses 
its velvety appearance. It may become hyperemic or dusky, 
as well as hypoperistaltic. Erythema may be focal or diffuse. 
The mucosa becomes friable, and diffuse ulcerations appear 
(Fig. 185-6). 
Histologically, there is a variable presence of lamina pro-
pria edema and villous blunting. However, the mononu-
clear cell infiltrates and cryptitis with apoptosis and regen-
eration are necessary for establishing the diagnosis of 
rejection. Neutrophils, e05inllphi\S, ;l!1d macrophages may 
be seen tril\'ersing the mlls(ulMis mucosa.'1 The degree of 
epithelial and crypt cell damage \·,lries. Complete mucosal 
sloughing and crypt destruction are seen in grafts with se-
vere rejection. The mucosal surface is partially replaced by 
inflammatory pseudomembranes and granulation tissue 
(Fig. 185-7). This may precipitate continuous blood loss as 
well as intermittent septic episodes from the damaged intes-
tine. 
Chronic rejection has been observed in patients with per-
sistent intractable rejection episodes. Clinically progressive 
weight loss, chronic diarrhea, intermittent fever, and gas-
trointestinal bleeding dominate the presentation, Histologi-
cally, villous blunting, focal ulcerations, epithelial metapl,l-
sia and scant cellular infiltrate are present on endoscopic 
mucosal biopsies. Full-thickness intestin;d biopSIes show 
obliterative thickening of intestinal arterioles. 
The incidence of acute intestinal allograft rejection during 
the first 90 days after transplantation is reported to be 80% 
in isolated small bowel recipients and 77% in liver-small 
I I 1-' <' _. 
bowel recipients. The incidenn' of acute liver allograit reJec-
tion in li\'l'r-small bowel recipients is 55%.21 
Crilft rl'jectilln is tTl'alec! initially with bolus steroid ther-
,'py (intr,l\'en()l1s hydrocorl!~oI1lD or methylprednisolone) ill 
cases ot mild rejection, with a ~tlDroid taper in cases of mod-
erate to se\'ere rejection. The FK-506 trough levels in plasm<, 
should reach 2 to 3 ng/mL by either the oral or intravenous 
routes. OKT3 is used when rejection has progressed with a 
steroid taper; however, it should be entertained as the initial 
therapeutic agent in cases of severe mucosal injury and 
crypt damage. 
Postoperative Hemorrhage 
Coagulopathy is more often illl intraoperative problem tklt 
relates to li\'er dysfunctJOIl, qualit,ltive <md quantitilti\'l' 
platelet defects, and fibrinolysis." Intraoperative bleeding is 
furthered by vascularized adhesions from previous surgery 
and portal hypertenSion. Temporary graft reperfusion co-
agulopathy mediated by plasminogen activators from the 
graft may occurY Efforts are taken to normalize these globill 
aspects of coagulation by the end of the operati\'e procedure 
so that in the absence of liver dysfunction, the coagulopathy 
is usually minor in the postoperative period. Postoperatin' 
intra-abdominal bleeding is most often a technical problem, 
arising from vascular anastomoses or extensive, raw perito-
neal surfaces. Certainly, coagulation should be normalized 
if postoperative bleeding occurs; if bleeding is proved, the 
origin should be presumed surgical and managed as such 
by early exploration. 
Biliary Complications 
Continuity of the biliary axis is preserved in multiviscerill 
and cluster grafts, whereils li\'er-'Illilll bowel and isolMni 
small bowel grafts require Roux'l'n- Y choledochojejul111'-
tomy. Correspondingly, these gratts (,111 dewlop biliJrY S\S' 
tem-related surgical complicatlolls (I.e., leilks and obstruc-
tions). 
Biliary leaks usually occur within the first 2 weeks ,lttl'r 
small bowel transplantation and may herald their presellll' 
with bilious drainage from the abdominal wound or dr,'!II' 
or merely with unexplained sepsis. The response to ex telll,d 
bilious drainage should be immediate exploration WIth sur-
gical revision of the biliarv dehiscellCl'. In the case oi unex-
plained sepsis in <Illy intestin,,1 trilllsplant recipient, all sur-
gical anastomoses should be r'ldiogrilphically inspectl'd 
(with percutaneous cholanglllgr<lphv), <1I1d it leilkage is sus-
pected, they should be openly rc\·isl'd. There is no place tor 
percutaneous diversion of biliary or intestinal leakage ill 
these patients, since both wound healing <,nd antimicf(li",,1 
immunity are impaired by multInlOdal iml11l1llotherap\' 
Biliary obstruction generallv follows <In anastomotic strIC' 
ture and is a delayed complication, but any clinical picture 
Figure 185-6. A, Normall'ndoscopic i'ppear.lncl' "I 
transplanted small intestine. Il, 'vloderate acutl' cl'liul,\f 
rejection of an intestinal <lliograft lit-ll1onstr,lting dillu'" 
edem., and focalervthL'ma. (:;l'l' Color 1'1,)((, Sellion "I 
this tl'xtbo"k) . 
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Figure 185-7. Acute c~ff~gar rejection. A, Endoscopic biopsy obtained 14 days after transplantation showed widening of the lamina propria 
with increased mononuclear cells, which were often cuffed around small vessels and infiltrating the crypt epithelium (arrow; hematoxylin 
and eosin, 140x). B, The reaction was more intense in biopsies that contained lymphoid nodules and where blastogenesis, focal 
ulcerations, congestion, and neutrophil plugging of capillaries were also seen (moderate acute cellular rejection; hematoxylin and eosin, 
140 x). C. Uncontrolled acute rejection eventually resulted in widespread mucosal destruction; the mucosa was replaced by granulation 
tissue. Note the overlying inflammatory pseudomembrane (arrow; hematoxylin and eosin, 350 X). 
that resembles cholangitis or biliary obstruction should be 
followed with cholilngiography to prm'e piltency, regardless 
of the timing ,liter tr,lnsplantiltion. 
Vascular Complications 
Major arterial thrombosis is a disastrous complication that 
leads to massive necrosis of the organs correspondingly 
supplied. Elevation of hepatic enzymes and pallor of the 
intestinal stoma are accompanied by clinical deterioration, 
fulminant sepsis, and hepatic coma. Isolated small bowel 
grafts can be removed with the expectation of patient recov-
ery, but in patients with composite grilfts, the event is usu-
ally fatal. Piltency of the arteries Can be rapidly confirmed 
with Doppler ultrasound examiniltion. 
Since the superior mesenteric vein-portal vein ilxis is pre-
served in the composite grilfts, \'enous outflow thrombosis 
is less likely to occur in piltients with them. Isolilted small 
bowel grafts hine iln anastomosis of these veins that can 
potentially occlude. Ascites, stomal congestion, and, ulti-
matelv, mesenteric infarction would be the ultimate result. 
\Jetther of these problems produces subtle clinical signs, 
ilnd diilgnosls should be prompt and obvious. In our series, 
thrombosis of the hepatIC artery hilS occurred in a pediatric 
recipient of a liver-small bowel grilft, with consequent he-
patic g;mgrene. This patient required retransplilntiltion of 
the liver component of the grilft, even though a full liver-
small bowel graft was desirable. 
Incomplete obstruction of major inflow or outflow vessels 
may be suspected on biopsy or based on clinical and labo-
riltory evidence of organ dysfunction. Contrast vascular 
studies are conhrmiltorv, and the correction is surgical or, 
in some GISeS, With balloon dilatation. 
Gastrointestinal Complications 
C,)stro111testll1al hlel'ding ,lttl'r intestinJI trJnspl,)J)tJtion is 
.li1 llJ))1J)Ol1S sign 1\1,)\ requires prompt .1ttentioll. Rl'jection lS 
the most probable cause and should be immediately diag-
nosed or ruled ou t on the basis of enteroscopic biopsy re-
sults. The di,1gnosis of rejection relies not only on histologic 
evidence but also on the endoscopic ilppearance (see Figs. 
185-6 ilnd 185-7). However, in the ,1bsence of any pathol-
ogy on endoscopy and with other supporting clinical evi-
dence of rejection, the patient should still be treated for 
acute rejection. 
Leakage of either the proximal or distal gastrointestinal 
anastomosis can occur in any recipient, but it is more com-
mon in pediatric patients than in adults. Any fresh surgical 
margin, including native duodenal ilnd colonic stumps and 
gastrostomy sites, ilre vulnerable to poor wound healing 
and subsequent leJkage. Presentation is often dramatic 
(florid sepsis), and confirmation is with radiologic contrast 
imaging. Surgical revision, evacuation of peritoneal soilage, 
and often re-exploration Me required to eliminate the con-
tilmination effectively. Again, sepsis without an obvious 
source should prompt the performance of contrast studies 
to document the integrity of all gastrointestinal anastomo-
ses; if the findings are inconclusive, diilgnostic laparotomy 
is indicated. 
Native gastric iltony and pylorospilsm that produce carly 
satiety or vomiting are common and self-limiting. Hyper-
motility of the allograft intestine occurs early after trilns-
plantation; in the absence of rejection or bacteriill over-
growth, it can be controlled with agents such as paregoric, 
loperamide, or pectin. Sudden changes in intestinal motility, 
particularly when accompanied by abdominal distention 
ilnd vomiting in the case of decreased motility, should initi-
ilte a search for rejection. 
Infections 
The trequency of infectious complic;)tions is high and is 
rl'sponsibiL> for signiiicant morbidity and mort;)lity Jfter in-
testinill transpl;mtJtion. This retlL'cts the rclati\'eiv higher 
Il'velll! Immunosuppression requirl'd to milint,llll thl' gr,1!t 
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Figure 185-8. A, Endoscopic appearance of cytomegaloviral enteritis is characterized by hyperemic erosions. B, The diagnosis was 
confirmed histologically by the presence of characteristic inclusions, by staining for viral antigens, or both. Note the focal neutrophilic 
inflammation (immunopefoxidase for cytomegalovirus antigens, 350 x). (See Color Plate Section of this textbook.) 
in these intestinal redpients. '8 Other predisposing factors 
include the severity of the preoperative liver failure (in mul-
tivisceral and liver-small bowel reCipients) as well as the 
presence of intra-abdominal, pulmonary, or intravenous 
line-induced sepsis before transplantation, Also, technically 
more difficult transplantation procedures with increased op-
erative time, transfusion requirements, and likelihood of re-
exploration reflect the advanced disease of these patients, 
Recipients of small bowel grafts have the lowest incidence 
of complications because of the more elective nature of their 
candidacv. 
Infectious pilthogens include bacteria, fungi, and viruses. 
Infections that present clinically relate (in order of fre-
quency) to intravenous lines, the abdominal wound, deep 
abdominal abscesses, peritonitis, and pneumonia. Bacterial 
translocation in grafts damaged by rejection illustrates the 
need for concomitant antirejection and antimicrobial ther-
apy and is a frequent source of infection. 
Of the bacterial pathogens, staphylococci and enterococci 
are common, whereas gram-negative rods usually accom-
pany polymicrobial infections. Not uncommonly, separate 
sources of infection occur Simultaneously, or mixed infec-
tions from the same source are present. This leads to multi-
ple antibiotic regimens and sets the stage for the develop-
ment of resistant organisms. Particularly problematic has 
been the nascent strain of panresistant enterococci. Persist-
ence of a physiologic hyperdynamic state in a patient being 
treated for proven infection should raise the suspicion of 
retained phlegmonous material in the abdomen or the pos-
sibility of rejection. 
Fungal infcctions become problematic ilfter heavy treat-
ment for rCJection, massive antibiotic uSilge, intestinal leaks, 
and multiple surgical explorations. The authors routinely 
employ low-dose amphotericin B prophylaxis in patients 
with these complications. Established fungal infections rc-
quire long-tcrm, full-dose antibiotic therilpy ilnd reduction 
or cessation of immunotherapy. All persistently septic recip-
ients are potential candidates for moderation of immu-
nosuppressant dosages if no coexistent cellular rejection is 
present. 
Clinical cytomegalovirus infection is commonly seen in 
adult intestinal gr<lft recipients and often involves the allo-
graft intestine (65% of the time). A cytomegalovirus-positive 
donor gr<llt trzlI1splanted into a cytomegalovirus-negative 
reCIpient is a significant risk factor, but intense bilseline 
immunosuppression with high FK-S06 levels and cumula-
tive doses of pulse steroids is a constant feature. Clinical 
presentation has generally been enteritis of variable severity 
with focal ulcerations and bleeding (Fig. 185-8). Neither 
prophylactic courses of ganciclovir therapy nor passive 
administration of immunoglobulin has been effective in 
preventing cytomegalovirus infection. A voidance of cyto-
megalovirus-positive grafts in cytomegalovirus-negative re-
cipients and the reduction of immunosuppression are oLir 
present strategy for controlling cytomegalovirus infections 
in intestinal graft recipients. 
Less commonly, respiratory syncytial virus, adenO\·irus, 
and parainfluenza virus have occurred in the pediatric pop· 
ulation. All viral infections are opportunistic and hilve as ,1 
"common denominator" the need for ilggressive treatment 
of rejection episodes in complicated patients with high 
Acute PhysiologiC and Chronic Health Evaluation scores. 
Post-transplantation lymphoproliferative disease associ· 
ated with the Epstein-Barr virus has occurred in three chil-
dren (6% of all patients and 11 % of pediatric patients) and 
resulted in one fatality. These patients presented with mul· 
tifocal disease and were treated with intravenous acyclovir 
or ganciclovir as well as with cessation of immunosl;ppres· 
sion. Rejection of the intestinal allograft may occur durin h 
the recovery phase and should be treated with steroids and 
reinstitution of FK-506 immunosuppression.'· 
Under the best of circumstances, the outlilY of fin<lnci,)i 
and time expenditures in composite and isolated small 
bowel transplant recipients is impressive. For best possible 
results, candidates who are nutritionally optimal and free III 
active infection should be selected. Donor organs should be 
discarded if they are less thJn perfect. Even with technicallv 
perfect operations, the managing physicians should expect 
iI panoply of postoperiltive difficulties Jnd be prepared to 
support these pJtients in all ways for an mdefinite peTioli <,I 
time. ManJging the balance between exccssive Jnd inildl'· 
quate immunosuppression in the face of potentially virull'nt 
infections, the pursuit of rejection and sources of infection, 
and maintenance of comprehensive critical care support arc 
the most chilllenging tilsks. 
References 
1. Grant D: Intl'stinJI tr"nspl"nlat;on: Current sl,)llIS rr,lIlspl,II11 
I'roc 11)89; 21:2R61)-287J. 
2. Liilehel IK. Cooll B. Miller FA: The phy~iologlc response of the 
small bowel of the dog to ischemia including prolonged in vitro 
preservation of the bowel with successful repl;lcement and sur-
vival. Ann Surg 1959; 150:5-13. 
3. Starzl TE. K,lUPP IIA Jr: Mass homotrK1n~piK1ntatiop of abdomi-
nal organs in dogs. Surg Forum 1%0; 11:1S-:\l1 
4. Starzl TE. Todo S. Tzakis A. d al: ,\bdominal organ cluster 
transplantation for the treatment of upper abdommal malignan-
cies. Ann Surg 1989; 210:374-386. 
5. Caine RY. Sells RA. Pena JR. et al: Introduction of immunologic 
tolerance by porcine liver allograft. Nature 1969; 223:472-474. 
6. Kamada N. Davies HS, Wight 0, et al: Liver transplantation in 
the rat: Biochemical and histological evidence of complete tol-
erance induction in nonrejector strains. Transplantation 1983; 
35:304-311. 
7. Starzl TE, Rowe M, Todo S, ct al: Tr<lnsplantation of multiple 
abdominal \'iscera. JAMA 1989; 261:1449-1457. 
8. Grant 0, Wall W, Mimeault R, et al: Successful small-bowell 
liver transplantation. Lancet 1990; 335:181-184. 
9. Goulet OK, Revillon Y, Jan 0, et al: Small-bowel transplantation 
in children. Transplant Proc 1990; 22:2499. 
10. Deitz E, Schroeder P, Gebhard H, et al: Successful clinical small 
bowel transplantation: Report of a case. Clin Transplant 1989; 
3:89. 
11. Oasis, Home Nutrition Support Patient Registry Annual Re-
port-1989 Data. Albany, NY, The Oley Foundation, 1991. 
12. Casella JF, Lewis JH, Bontl!mpo FA, et al: Successful treatment 
for homozygous protein C deficiency by hepatic transplanta-
tion. Lancet 1988; i:435-438. 
I3. StaTZI TE, Todo S, Tzakis A, et al: The manv faces of multivis-
ceral transplantation. Surg Gynecol Obstet 1991; 172:335-344. 
14. Tzakis A, Todo S, Starzl TE: Piggyback orthotopic liver trans-
plantation with preservation of the inferior vena cava. Ann 
Surg 1989; 210:649-652. 
15. Todo S, Tzakis A, Abu-Elmagd K, et al: Intestinal transplanta-
tion in composite visceral grafts or alone. Ann Surg 1992; 
216:223-234. 
16. Takaya S, Iwaki Y, Starzl TE: Liver tran~pl~ntati"n in positive 
cytotoxic crossmatch cases using FK50(,. high dosl' ,teroids, and 
prostaglandin E,. Transplant,ltion 1991; R4:9~T-9PPK 
17. Karavias 0, Jabbour N, Felekouras E. l'I al: Right diaphragmatiC 
paralysis following orthotopic liver transplantation. Submitted. 
18. Reyes J, Abu-Elmagd K, Tzakis A. et al: InfectiOUs complica-
tions after human small bowel transplantation. Transplant Proc 
1992; 24:1249-1250. 
18a. Green M, Reyes J, Nour B, et al: Earlv infectious complications 
of liver-intestinal transplantation in children: Preliminary anal-
ysis. Transplant Proc 1994; 26:1420-1421. 
19. Reyes J, Tzakis AG, Todo S, et al: Nutritional management of 
intestinal transplant reCipients. Transplant Proc 1993; 25:1200-
1201. 
20. Abu·Elmagd K, Tzakis A, Todo S, et .11: Monitoring and trl'at-
ment of intestinal allograft rejection in humans. Tr,lnsplant I'roc 
1993; 25: 1202-1203. 
21. Nak;lnlUra K. Abu-Elmagd K. Todo S. l't al: [)athlllogv of hu-
man small intestinal transpluntation: Alonl' or In combination 
with the liver. Submitted. 
22. Kang YG, Martin OJ, Marquez jM, et ill: Intraoperative changes 
in blood coagulation and thromboelastogruphic monitoring in 
liver transplantation. Anesth Analg 1985; 64:888 
23. Stahl RL, Duncan A, Hooks MA, et al: A hvpl'rcoagulable statl' 
follows orthotopic liver transplantation. f lepatology 1990; 
12:553. 
24. Reyes J, Tzakis A, Bonet H, et al: Lymphoprnlifl'rati\"l' disease 
,lfter intestinal transplantation under FK50h immunosuppres-
sion. Transplant Proc 1994; 26:1426-1427. 
BONE \lARROW TRANSI'L;\NTATION 1687 
.-CHAPTER 186 
Bone Marrow Transplantation 
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Bone marrow transplantation (BMT) is increasingly used in 
the treatment of certain malignant as well as nonmalignant 
disorders (Table 186-1). The basic strategy is to give very 
high doses of drugs or radiation or both to ablilte malignant 
cells or the host's Iymphohematopoietic system, iollowed 
by infusion of normal stem cells. The source oi these cells 
can be a human leukocyte antigen (HLA)-identical sibling 
or a partially or fully HLA-identical related or matched 
unrelated donor (MUD). These are called allogeneic BMT. 
A twin donor is sometimes used (syngeneic transplant). In 
autologous BMT, the recipient's bone marrow (BM) or 
blood-derived stem cells are used. The choice between an 
autologous or allogeneic BMT depends on many issues, in-
cluding the disease state, the availability of a suitable donor, 
and the risk-benefit analysis for eac;, patient. The age of 
BMT recipients has been increasing. Allogeneic BMT is now 
performed in patients up to 55 years of age. Autologous 
BMT can probably be performed up to age 70. This chapter 
reviews the major indications and problems associated with 
BMT and attempts to address the main issues in treatment 
of patients undergoing BMT. 
INDICA TIONS 
The indicJtions for BMT arc steadily illcrt.'Jsillg. 13\1T \VJS 
first applied to the leukemias and immune deiiciency disor-
ders (including aplastic anemia), but the indications have 
expanded to include lymphoma, solid tumors, <1nd genetic 
diseases. As BMT becomes safer, the indications and the 
numbers of patients treated will most likely continue to 
increase. Some of the current indications for BMT are shown 
in Table 186-1. 
ACUTE LEUKEMIA. Complete remission (CR) rates of 70% 
to 80% are achieved in the majority of piltients with i1cute 
myelogenous leukemia (AML). Cure of AML can only be 
obtained with additional therapy. Direct comparisons of the 
different modalities of treatment for p<1tients with AML in 
first CR have been difficult to assess. It is vet unclciIT 
whether BMT (autologous or allogeneic from HLA-identic<11 
sibling) would result in long-term leukemia-free sur\'iv<11 
superior to that with chemotherapy in patients with AML 
in first CR when various prognostic variables are tilken into 
account. I Studies addressing this issue are under way. 
TABLE 186-1. Disorders Treated with Bone Marrow 
Transplantation 
Maligllallt Disorders 
Acute leukemia 
Chronic myelogenous leukemia 
Myelodysplastic syndrome 
Lymphomas 
Solid tumors 
NOlllllll/igllllllt Disorders 
Aplastic anemia 
fmmullEFlo~ic diSlucil'rs 
~lemoglEFblnopathi<Ds 
Metabolic disorders 
